Future growth expectations in earnings/operating earnings/profits/EPS?

OneSource Specialty Pharma anticipates strong revenue growth, targeting $400 million by FY '28, with a 30% CAGR from FY '25 to '28. EBITDA margins are expected to remain steady around 38% to 40%, demonstrating strong operating leverage. FY '26 is seen as a transitional year with commercial launches ramping up in H2, leading to lumpy quarterly performance but a strong exit run rate. Adjusted PAT improved significantly in FY '25, and EPS stands at INR21.4 for full year, with further growth expected as DDC projects move from milestone to commercial stages. Long-term, the company aims to be net de

Current/ Expected Orderbook/ Pending Orders?

OneSource Specialty Pharma has a strong and growing order book with around 50 ongoing drug-device combination (DDC) projects, including both fully delivered and in-execution. The order book is aligned with customers' forecasts and patent expiries over the next 2-3 years, supporting capacity ramp-up. The company is actively adding capacity, aiming to nearly double rated capacity from about 40 million to over 90 million by the end of 2025. Capacity expansions are primarily to serve ongoing Master Service Agreements (MSAs) and Customer-Specific Agreements (CSAs). Customers have provided take-or-p

Any current/future new fundraising through debt or equity?

OneSource Specialty Pharma Limited is investing over $100 million over the next couple of years to expand capacity and capabilities. They are consciously balancing leverage and access to funds on attractive terms with internal accruals and customer participation. The company has significantly reduced high-cost debt, cutting it by almost 50% by the end of the last quarter (net of cash and cash equivalents). Current net debt stands at INR4,707 million. Interest costs have decreased by 20% quarter-over-quarter due to better credit rating and access to economical funds. The company aims to be net

Any current/future capex/capital investment/strategic investment?

OneSource Specialty Pharma plans to invest over $100 million over the next couple of years to expand capacity and capabilities. Capacity is being increased from a rated 40 million to over 90 million by December 2025. Capacity additions are primarily in India, but the company is open to exploring expansion outside India, both organically and inorganically. Customer participation in capex is part of arrangements to secure capacity (e.g., take-or-pay contracts, reservation fees). The company is adding new capabilities, such as high-viscous pre-filled syringes, within its broader platform. Investm

Future growth expectations in sales/revenue/volumes?

OneSource Specialty Pharma aims for $400 million in sales revenue by FY 2028, maintaining 38%-40% EBITDA margin. Strong order book supports significant capacity expansion from 40 million to over 90 million units by December 2025. FY 2026 is a transition year with lumpy revenue due to regulatory approvals; stronger H2 expected, mirroring FY 2025 pattern. Customer forecasts and patent expiries guide capacity ramp-up; near full utilization expected as commercial launches increase. Anticipated launches of key products like Liraglutide, Teriparatide, and Semaglutide generics in FY 2026 across multi

IN US

Sale is live|00:00:00left today

OneSource Specialty Pharma LtdQ1 FY25Pharmaceuticals & Biotechnology

OneSource Specialty Pharma Ltd Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,568Market Cap: ₹21.0K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Yes

Order

Yes

Capex

Yes

3 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→OneSource Specialty Pharma aims for $400 million in sales revenue by FY 2028, maintaining 38%-40% EBITDA margin.
→Strong order book supports significant capacity expansion from 40 million to over 90 million units by December 2025.
→FY 2026 is a transition year with lumpy revenue due to regulatory approvals; stronger H2 expected, mirroring FY 2025 pattern.
→Customer forecasts and patent expiries guide capacity ramp-up; near full utilization expected as commercial launches increase.
→Anticipated launches of key products like Liraglutide, Teriparatide, and Semaglutide generics in FY 2026 across multiple markets.
→Market expansion driven by increased access in underserved regions (e.g., Brazil and Canada), with 4-12x potential volume growth.
→Investment of over $100 million underway for capacity and capability expansion to support future growth.
→New therapies, especially injectables, expected to sustain demand; oral therapy share capped at ~25%.

Margin guidance

Category 3

→OneSource Specialty Pharma anticipates strong revenue growth, targeting $400 million by FY '28, with a 30% CAGR from FY '25 to '28.
→EBITDA margins are expected to remain steady around 38% to 40%, demonstrating strong operating leverage.
→FY '26 is seen as a transitional year with commercial launches ramping up in H2, leading to lumpy quarterly performance but a strong exit run rate.
→Adjusted PAT improved significantly in FY '25, and EPS stands at INR21.4 for full year, with further growth expected as DDC projects move from milestone to commercial stages.
→Long-term, the company aims to be net debt free in 2-3 years, strengthening financial health.
→NBE (biologics) commercialization expected between FY '28 and '29, with limited near-term revenue impact.
→Overall, strong order book and capacity expansions support confidence in achieving near-term growth and profitability targets.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→OneSource Specialty Pharma Limited is investing over $100 million over the next couple of years to expand capacity and capabilities.
→They are consciously balancing leverage and access to funds on attractive terms with internal accruals and customer participation.
→The company has significantly reduced high-cost debt, cutting it by almost 50% by the end of the last quarter (net of cash and cash equivalents).
→Current net debt stands at INR4,707 million.
→Interest costs have decreased by 20% quarter-over-quarter due to better credit rating and access to economical funds.
→The company aims to be net debt free within 2 to 3 years.
→No specific mentions of new fundraising through debt or equity at present; focus is on maintaining healthy leverage and using internal and customer funds for growth investments.

Order book

Yes

→OneSource Specialty Pharma has a strong and growing order book with around 50 ongoing drug-device combination (DDC) projects, including both fully delivered and in-execution.
→The order book is aligned with customers' forecasts and patent expiries over the next 2-3 years, supporting capacity ramp-up.
→The company is actively adding capacity, aiming to nearly double rated capacity from about 40 million to over 90 million by the end of 2025.
→Capacity expansions are primarily to serve ongoing Master Service Agreements (MSAs) and Customer-Specific Agreements (CSAs).
→Customers have provided take-or-pay contracts and long-term forecasts, ensuring secured capacity allocations.
→The robust order book underpins the company’s FY '28 guidance of $400 million in sales, supporting continued growth through FY '26 and into FY '27.
→The broad and diverse customer base reduces dependency on any single approval or market.

Capex plans

Yes

→OneSource Specialty Pharma plans to invest over $100 million over the next couple of years to expand capacity and capabilities.
→Capacity is being increased from a rated 40 million to over 90 million by December 2025.
→Capacity additions are primarily in India, but the company is open to exploring expansion outside India, both organically and inorganically.
→Customer participation in capex is part of arrangements to secure capacity (e.g., take-or-pay contracts, reservation fees).
→The company is adding new capabilities, such as high-viscous pre-filled syringes, within its broader platform.
→Investments also include integration programs, upgrading IT systems, and improving digitalization and quality standards.
→The company targets debt reduction aligned with capex and has reduced net debt to INR4,707 million as of March 2025, aiming for net debt-free status in 2-3 years.

How does OneSource Specialty Pharma Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1OneSource Specialty Pharma Ltd

Rev 2Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like OneSource Specialty Pharma Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio